BRIEF-Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted

* Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.